Navigation Links
VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
Date:8/25/2008

BOSTON, Aug. 25 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP), entitled, "Creating Value; Turnaround Leverages Product Opportunities while Expectation Abounds and Losses Decrease."

This review is available at website: http://www.scimitarequity.com

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment of dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT: Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
11. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2019)... ... June 12, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, is excited to announce that ... grant exclusive rights for Zillion to represent LDA in all of China. ...
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements ... an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings for more ... educate viewers about how its technology facilitates laboratories to improve efficiency and quality ...
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... engagement, and Carilion Clinic, a national leader in opioid treatment, announced today they ... care. , Mytonomy recently deployed its virtual care platform at the ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ ... a test on mice, MSC-EVs also increased the cells’ ability to lodge into ...
Breaking Biology Technology:
(Date:7/9/2019)... ... July 08, 2019 , ... KMK ... hub of Cambridge, MA. This expansion strengthens KMK’s presence for the sales, support, ... sales force effectiveness consulting for the biotechnology corridor. With this expansion, ...
(Date:6/24/2019)... ... ... According to the World Health Organization , over a million people are ... (or "trich") and syphilis. And that’s not counting HIV. , In 2017, the ... largest number of HIV diagnoses (9,807), followed by Hispanic/Latino men (7,436) and White men ...
(Date:6/16/2019)... , ... June 14, 2019 , ... ... Oracle Cloud customer, will deliver a joint presentation with Versiti’s CIO at the ... 16-19 at the Rosen Shingle Creek Resort. , Versiti Vice President and Chief ...
Breaking Biology News(10 mins):